The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
ECHELON-2 试验:一项随机 III 期研究,探讨 brentuximab vedotin 与化疗联合治疗 CD30 阳性外周 T 细胞淋巴瘤的 5 年结果
期刊:Annals of Oncology
影响因子:56.7
doi:10.1016/j.annonc.2021.12.002
S Horwitz, O A O'Connor, B Pro, L Trümper, S Iyer, R Advani, N L Bartlett, J H Christensen, F Morschhauser, E Domingo-Domenech, G Rossi, W S Kim, T Feldman, T Menne, D Belada, Á Illés, K Tobinai, K Tsukasaki, S-P Yeh, A Shustov, A Hüttmann, K J Savage, S Yuen, P L Zinzani, H Miao, V Bunn, K Fenton,